Establishment of novel immunotherapy against gynecologic cancer based on the mechanism of maternal-fetal immune tolerance.
| Project/Area Number |
25861467
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Akita University |
|---|
Principal Investigator |
Shimizu Dai 秋田大学, 医学部, 講師 (60400503)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 母児免疫寛容 / 癌免疫療法 |
|---|
| Outline of Final Research Achievements |
We investigated the expression of HLA-G in human gynecologic cancer cell-lines and identified its expression in cervical cancer cell-line, Hela and ovarian cancer cell-line, SK-OV-3 by RT-PCR. We also established their stable transfectants that integrated luciferase reporter gene. We examined cytotoxic assay of NK cell (NK-92: human NK cell-line derived from non-hodgkin’s lymphoma) by co-culture with human gynecologic cancer cells with or without anti-HLA-G neutralization antibody. We continue the examination aim at the clinical application of our strategy against cancer.
|
Report
(4 results)
Research Products
(6 results)
